Bluebird Bio Gets Relief, But Gene Therapy Hurdles Remain

Sickle Cell Patient’s AML Likely Unrelated To LentiGlobin

 
• By Alaric DeArment

The jury is still out on the case of MDS and some remaining questions regarding the AML case may still hinder commercial uptake.

Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells
An analyses by bluebird bio probably rules out its gene therapy as the culprit behind a patient in its SCD study developing acute myeloid leukemia • Source: Shutterstock

More from R&D

More from Scrip